In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 291 to 300 of 303

TitleTypeExpected publication date
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]Technology appraisal guidanceTBC
Venglustat for treating gangliosidoses in people 2 years and over ID 6358Technology appraisal guidanceTBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]Technology appraisal guidanceTBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]Technology appraisal guidanceTBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]Technology appraisal guidance
Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy [ID6470]Technology appraisal guidanceTBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]Technology appraisal guidance
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]Technology appraisal guidanceTBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]Technology appraisal guidance
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All